Total Payments
$11,294
2022 Payments
$22.00
Companies
5
Transactions
9
Medicare Patients
7,181
Medicare Billing
$1.6M
Payment Breakdown by Category
Research$11,093 (98.2%)
Food & Beverage$126.17 (1.1%)
Education$74.67 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,093 | 4 | 98.2% |
| Food and Beverage | $126.17 | 2 | 1.1% |
| Education | $74.67 | 3 | 0.7% |
Payments by Type
Research
$11,093
4 transactions
General
$200.84
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $11,093 | 4 | $0 (2022) |
| Amgen Inc. | $126.17 | 2 | $0 (2018) |
| Astellas Pharma US Inc | $51.00 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $11.75 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $22.00 | 1 | Eli Lilly and Company ($22.00) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $62.75 | 2 | Astellas Pharma US Inc ($51.00) |
| 2019 | $2,234 | 1 | Eli Lilly and Company ($2,234) |
| 2018 | $7,977 | 2 | Eli Lilly and Company ($7,886) |
| 2017 | $986.02 | 2 | Eli Lilly and Company ($951.18) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2022 | Eli Lilly and Company | — | — | In-kind items and services | $22.00 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 12/21/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $51.00 | General |
| 08/21/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $11.75 | General |
| Category: Oncology | ||||||
| 01/08/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,234.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 09/19/2018 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $91.33 | General |
| Category: Oncology | ||||||
| 01/30/2018 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,886.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 11/16/2017 | Amgen Inc. | Neulasta (Biological), NEUPOGEN, Vectibix | Food and Beverage | In-kind items and services | $34.84 | General |
| Category: Oncology | ||||||
| 09/27/2017 | Eli Lilly and Company | — | — | In-kind items and services | $951.18 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $11,071 | 3 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $22.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 1,755 | 23,979 | $2.5M | $633,231 |
| 2022 | 32 | 1,351 | 11,285 | $1.1M | $258,299 |
| 2021 | 44 | 1,709 | 14,245 | $862,681 | $191,030 |
| 2020 | 52 | 2,366 | 25,882 | $2.0M | $514,783 |
Total Patients
7,181
Total Services
75,391
Medicare Billing
$1.6M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 7 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 86300 | Immunologic analysis for detection of tumor antigen | Office | 2020 | 13 | 24 | $2,976 | $497.34 | 16.7% |
| 80048 | Blood test, basic group of blood chemicals | Office | 2020 | 29 | 53 | $2,544 | $434.42 | 17.1% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2020 | 11 | 22 | $2,112 | $414.46 | 19.6% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 12 | 17 | $2,397 | $398.25 | 16.6% |
| 82746 | Folic acid level | Office | 2020 | 27 | 27 | $1,917 | $395.16 | 20.6% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2020 | 26 | 26 | $1,924 | $390.28 | 20.3% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2020 | 17 | 23 | $1,794 | $383.68 | 21.4% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 11 | 56 | $1,848 | $359.98 | 19.5% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2020 | 11 | 13 | $1,443 | $281.69 | 19.5% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2020 | 11 | 203 | $2,498 | $255.51 | 10.2% |
| 96361 | Hydration infusion into a vein | Office | 2020 | 16 | 21 | $1,533 | $209.90 | 13.7% |
| 85046 | Red blood count automated, with additional calculations | Office | 2020 | 18 | 31 | $775.00 | $172.23 | 22.2% |
| J9181 | Injection, etoposide, 10 mg | Office | 2020 | 11 | 290 | $2,900 | $151.28 | 5.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2020 | 55 | 1,270 | $1,270 | $124.40 | 9.8% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2020 | 20 | 470 | $11,750 | $106.83 | 0.9% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2020 | 20 | 27 | $513.00 | $52.98 | 10.3% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2020 | 36 | 80 | $391.00 | $50.04 | 12.8% |
| J3490 | Unclassified drugs | Office | 2020 | 13 | 22 | $198.00 | $14.08 | 7.1% |
About Dr. Miho Dougherty, M.D
Dr. Miho Dougherty, M.D is a Internal Medicine healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/21/2009. The National Provider Identifier (NPI) number assigned to this provider is 1184950479.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Miho Dougherty, M.D has received a total of $11,294 in payments from pharmaceutical and medical device companies, with $22.00 received in 2022. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "" ($11,093).
As a Medicare-enrolled provider, Dougherty has provided services to 7,181 Medicare beneficiaries, totaling 75,391 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Eugene, OR
- Active Since 10/21/2009
- Last Updated 07/15/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184950479
Products in Payments
- Kyprolis (Biological) $91.33
- Neulasta (Biological) $34.84
- OPDIVO (Biological) $11.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Eugene
Luke Fletcher, Md, MD
Internal Medicine — Payments: $29,592
Internal Medicine $29,592
Karthik Mahadevan, Md, MD
Internal Medicine — Payments: $6,925
Internal Medicine $6,925
Kirk Jacobson, M.d, M.D
Internal Medicine — Payments: $5,643
Internal Medicine $5,643
Dr. Shehzad Jinnah, Md, MD
Internal Medicine — Payments: $3,561
Internal Medicine $3,561
Dr. Jane Mossberg, M.d, M.D
Internal Medicine — Payments: $2,402
Internal Medicine $2,402
Paul Ehrlich, Do, DO
Internal Medicine — Payments: $1,300
Internal Medicine $1,300